NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06360575 2026-03-20
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357975 2026-03-19
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03620643 2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04030429 2025-07-16
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
National Cheng-Kung University Hospital
Phase 2 Terminated
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting